To learn more, please call our Research Department at (513) 936-5388 or (888) 649-4800. Or email abradley@ohcmail.com
FIRST LINE, not eligible for High Dose Chemotherapy
- Study number:
- MM 23 SCRI
- Protocol title:
- Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-line Treatment of Patients with Multiple Myeloma Who are not Candidates for High Dose Chemotherapy
- Status:
- Open